title: Hepatitis C genotype 1.
abstract: OBJECTIVE
  To assess advances in the treatment of genotype 1 (G1 hepatitis C virus), in particular, the development of new interferon (and ribavirin)-free treatment regimes.
  
  
  RESULTS
  The treatment of hepatitis C has advanced rapidly over the last 24 months. Newer interferon-containing regimes have been developed with improved tolerability, and interferon-free regimes with outstanding efficacy and improved tolerability have been developed.
  
  
  CONCLUSIONS
  New treatment regimes for hepatitis C virus have significantly altered the outlook for patients with hepatitis C. New interferon-containing treatment regimes with simeprevir and sofosbuvir, which have improved response rates, have shorter treatment durations and fewer side-effects are becoming available, and interferon-free regimes have been developed. The interferon-free regimes involve multidrug combinations or two-drug combinations and offer the possibility of shorter treatment duration with 8 or 12 weeks. The efficacy of the interferon-free regimes is striking with response rates of well over 90% reported in a wide range of different patient populations. The rapid progress in the treatment of hepatitis C will hopefully result in a cure for most patients, thereby significantly decreasing the morbidity and mortality associated with hepatitis C virus infection.
authors.affiliation: Barts and The London School of Medicine, London, United Kingdom.
authors.forename: Graham R
authors.initials: GR
authors.lastname: Foster
authors.forename: Sampath
authors.initials: S
authors.lastname: De Silva
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage*; D003362:Cost-Benefit Analysis; D004279:DNA, Viral / Q000187:drug effects / Q000235:genetics; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005838:Genotype; D016174:Hepacivirus / Q000187:drug effects / Q000235:genetics / Q000276:immunology*; D019698:Hepatitis C, Chronic / Q000188:drug therapy / Q000235:genetics / Q000276:immunology*; D006575:Heterocyclic Compounds, 3-Ring / Q000008:administration & dosage*; D006801:Humans; D012367:RNA, Viral / Q000187:drug effects / Q000235:genetics; D012254:Ribavirin / Q000008:administration & dosage*; D000069616:Simeprevir; D000069474:Sofosbuvir; D013449:Sulfonamides / Q000008:administration & dosage*; D016896:Treatment Outcome; D014542:Uridine Monophosphate / Q000008:administration & dosage / Q000031:analogs & derivatives*; D019562:Viral Load
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral; D006575:Heterocyclic Compounds, 3-Ring; D012367:RNA, Viral; D013449:Sulfonamides; D012254:Ribavirin; D000069616:Simeprevir; D014542:Uridine Monophosphate; D000069474:Sofosbuvir